Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma: Real-life Experience from a Single Tertiary Centre in Spain and ALBI Score as a Survival Prognostic Factor
The initial experience with atez/bev at our center demonstrated poorer outcomes compared to the original trial (IMbrave150). A careful assessment of the ALBI score may serve as a crucial factor in the selection of systemic treatment for patients with HCC.
Authors
- Carlos R. Abril (ORCID: https://orcid.org/0000-0003-3012-535X)
- Manuel Alós
- Cristina Montón
- Joan Toscá (ORCID: https://orcid.org/0000-0003-1258-9513)
- Paloma Lluch (ORCID: https://orcid.org/0000-0003-3192-3820)
- Víctor Merino
- Gloria Segarra
- Nuria Casasus
- María Pilar Ballester
Institutions
- Universitat de València (ES)
- Hospital Clínico Universitario de Valencia (ES)
- INCLIVA Health Research Institute (ES)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2024-09-01
- DOI
- https://doi.org/10.21873/cdp.10373
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37